Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (303)	3/12/2000 1:23:00 AM
From: RWReeves	Read Replies (2) \| Respond to of 513

Some Recent AVAN patents US06015563 01/18/2000 Polyphosphazene polyelectrolyte immunoadjuvants US05981481 11/09/1999 Human C3b/C4b receptor (CR1) US05958414 09/28/1999 Composition to protect a mammal against Bartonella henselae infection US05958410 09/28/1999 Therapy of sarcoidosis '563 is the interesting one and has been ref'd in 8 patents. The balance seems to be TCEL patents including the slew of complement inhibitors. US05976540 11/02/1999 Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions US05858969 01/12/1999 Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1) US05856300 01/05/1999 Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions US05840858 11/24/1998 Protein purification using immobilized metal affinity chromatography for complement receptor proteins US05808109 09/15/1998 Compounds that inhibit complement and/or suppress immune activity US05656659 08/12/1997 Compounds which inhibit complement and/or suppress immune activity US05601822 02/11/1997 .gamma., .delta. T cell receptor and methods for detection US05552300 09/03/1996 T cell antigen receptor V region proteins and methods of preparation thereof 80% US05506247 04/09/1996 Compounds that inhibit complement and/or suppress immune activity US05456909 10/10/1995 Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo US05436319 07/25/1995 Cell free T cell antigen receptor beta chain and its clinical utilities US05401767 03/28/1995 Compounds which inhibit complement and/or suppress immune activity US05366986 11/22/1994 Compounds which inhibit complement and/or suppress immune activity US05340921 08/23/1994 .GAMMA., .delta.T cell receptor and methods and detection US05223426 06/29/1993 Monoclonal antibodies reactive with defined regions of the T-cell antigen receptor 80% US05185250 02/09/1993 Human .gamma., .delta.T cell antigen receptor polypeptides and nucleic acids US05173499 12/22/1992 Compounds which inhibit complement and/or suppress immune activity US05024940 06/18/1991 Nucleic acids encoding the delta chain of the T cell antigen receptor US05006459 04/09/1991 Therapeutic and diagnostic methods using soluble T cell surface molecules US04845026 07/04/1989 Assay systems for detecting cell-free T cell antigen receptor related molecules and the clinical utilities of the assays plus a few more. And VRI of course. RWR